WO2014163717A1 - Extraits de hoya carnosa et procédés d'utilisation - Google Patents

Extraits de hoya carnosa et procédés d'utilisation Download PDF

Info

Publication number
WO2014163717A1
WO2014163717A1 PCT/US2014/010056 US2014010056W WO2014163717A1 WO 2014163717 A1 WO2014163717 A1 WO 2014163717A1 US 2014010056 W US2014010056 W US 2014010056W WO 2014163717 A1 WO2014163717 A1 WO 2014163717A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
extract
aging
composition
hoya carnosa
Prior art date
Application number
PCT/US2014/010056
Other languages
English (en)
Inventor
Qian Zheng
John W. Lyga
Uma Santhanam
Ying Chen
Original Assignee
Avon Products, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/793,177 external-priority patent/US8865231B2/en
Application filed by Avon Products, Inc. filed Critical Avon Products, Inc.
Publication of WO2014163717A1 publication Critical patent/WO2014163717A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]

Definitions

  • the present invention relates generally to cosmetic compositions incorporating Hoya carnosa extracts and their use to reduce fine lines and wrinkles, improve sagging, enhance lifting, and improve skin tone and to improve the overall appearance of skin by increasing epidermis thickness and stimulating the production of collagen, and/or by inducing lipogenesis.
  • Human skin is broadly divided into two layers: the surface epidermis which provides an anatomical barrier to foreign elements and maintains the body's internal environment, and the underlying dermis which provides nutritional and structural support to the epidermis.
  • the epidermis mainly consists of keratinocytes and is comprised of several sub-layers (from the innermost outwards): Stratum germinativum/Stratum basale, Stratum spinosum, Stratum granulosum, and Stratum corneum.
  • the keratinocytes generated by the mitosis of keratinocyte stem cells, originate in the stratum basale and then push up through the strata.
  • keratinocytes As these cells move to the surface of the skin they undergo gradual differentiation, becoming anucleated, flattened, and highly keratinized. During this process the keratinocytes become highly organized. They form desmosomes, cellular junctions, between each other and, through the excretion of keratin proteins and lipids, form an extracellular matrix which strengthens the skin. Eventually the keratinocytes die off and form the stratum corneum. In healthy skin, keratinocytes are shed and replaced continuously every 30 days.
  • the dermis is the underlying layer of the skin located between the epidermis and subcutaneous tissue. Since the epidermis lacks blood vessels, the cells of the epidermis rely upon the blood vessels in the dermis for their nutrients and oxygen.
  • the dermal-epidermal junction (DEJ) is a specialized structure that maintains close contact between the lamina densa, a layer of extracellular matrix upon which the epithelium sits, and the underlying connective tissue of the dermis.
  • the DEJ is comprised mainly of collagen and elastin and structured as interlocking finger- like projections from the epidermis and dermal layers called Rete ridges.
  • the Rete ridges increase the surface area of the epidermis exposed to the dermis at the DEJ, so that the transfer of necessary nutrients/oxygen is more efficient, and the two layers of the skin form a strong bond that resists mechanical stress (shear).
  • the dermis is the thickest of the skin layers and comprises the extracellular matrix of the skin, which is maintained by fibroblast cells. Fibroblasts maintain the structural integrity of connective tissues by continuously secreting precursors of the extracellular matrix.
  • the main structural component of the dermis is a protein called collagen. Bundles of collagen molecules pack together throughout the dermis, accounting for three-fourths of the dry weight of skin.
  • Collagen has great tensile strength; along with soft keratin, it is responsible for skin strength and elasticity.
  • soft keratin it is responsible for skin strength and elasticity.
  • the resulting collagen deficiency may lead to reduction in skin strength and elasticity. Further, given that collagen is a major component of the DEJ, the DEJ flattens out with aging, such that the skin is more fragile and more likely to shear. As the DEJ flattens the amount of nutrients/oxygen transferred to the epidermis through the DEJ is reduced because the surface area in contact with the epidermis shrinks. The reduction of HA within the epidermis extracellular matrix reduces the epidermis's ability to transfer the available nutrients/oxygen to its cells. This inefficient nutrient/oxygen transport impacts the keratinocytes of the epidermis.
  • the keratinocytes renewal rate is reduced and as a consequence the stratum corneum loses its capacity to retain moisture and the skin dehydrates.
  • aged or aging skin may exhibit lines and wrinkles, sagging, dullness, discoloration, uneven tone, rough texture, and the like. Additionally, aged or aging skin exhibits less strength and flexibility and is more fragile. These signs of aging may be exacerbated by common medications such as those prescribed for the treatment of Parkinson's disease, i.e. Levodopa, or menopause, i.e. hormone therapies.
  • the skin, epidermis and dermis are supported by a layer of subcutaneous fat that insulates and cushions the body from external forces.
  • the subcutaneous fat is comprised of adipocytes (fat cells), arranged in chambers or lobules separated by fibrous septa
  • Subcutaneous adipose tissue is crucial for maintaining facial volume and fullness. Loss of subcutaneous fat that is associated with pathological lipoatrophy or aging leads to facial sagging, sunken appearance and wrinkles and folds on the face.
  • dermatological procedures such as lipofilling and lipografting are used to address loss of facial volume and correct facial contour.
  • the subcutaneous fat of the face is partitioned into discrete anatomic compartments.
  • Facial aging is, in part, characterized by how these compartments change with age. It has been shown that with aging (as well as with exposure to UV and oxidative stress) the thin layer of fat under skin is damaged, leading to facial sagging and aged look. On the cellular level it was shown that the ability of preadipocytes to differentiate into mature adipocytes declines with age.
  • Hoya carnosa the wax plant, is a species in the dogbane family (Apocynaceae). It is native to Eastern Asia and Australia. Hoya carnosa has star- shaped light pink flowers covered in tiny hairs that are borne in clusters. They are heavily scented.
  • compositions comprising and extract of Hoya carnosa may stimulate lipid production ("lipogenesis") in the skin.
  • lipogenesis lipid production
  • Such compositions will be particularly suitable for the treatment and prevention of the loss of subcutaneous fat, and in particular, facial fat loss, sagging skin, wrinkles, dry skin, and the like.
  • One embodiment of the current invention relates to a topical composition including a Hoya carnosa plant extract; and a cosmetically, dermatologically, pharmaceutically, or physiologically acceptable vehicle.
  • the plant extract may be from the whole of the Hoya carnosa plant.
  • the composition may be an aerosol spray, cream, emulsion, solid, liquid, dispersion, foam, gel, lotion, mousse, ointment, powder, patch, pomade, solution, pump spray, stick or towelette.
  • the plant extract may be present in the composition in an amount sufficient to increase collagen proliferation, increase epidermis thickness, or any combination thereof.
  • the plant extract may be present in an amount from about 0.0001 wt % to about 90 wt %, based on the total weight of the composition, and in a further embodiment, the plant extract may be present in an amount from about 0.01 wt% to about 10 wt %, based on the total weight of the composition.
  • the plant extract may be in an amount sufficient to alleviate the aesthetic appearance of wrinkles, pigment spots, skin sagging, loss of skin elasticity, mottled skin appearance or any combination thereof.
  • a further embodiment of the current invention relates to a method of improving the aesthetic appearance of an aging skin in need thereof, by topically applying to the skin the above-noted composition in an amount effective to improve the aesthetic appearance of skin.
  • the skin is sensitive skin.
  • the composition is topically applied to the skin at least once daily for at least one week.
  • compositions incorporating Hoya carnosa extracts are used to ameliorate, inhibit, delay, reduce, and/or improve the signs of subcutaneous fat loss, and accordingly find use as potent lipogenic products, and in particular aesthetic facial appearance improvement products.
  • the aging may be due to chronological, hormonal, or environmental effects.
  • the improvement in aesthetic appearance is selected from the group of: (a) treatment, reduction, and/or prevention of fine lines or wrinkles; (b) reduction of skin pore size; (c) improvement in skin thickness, plumpness, and/or tautness; (d) improvement in skin suppleness and/or softness; (e) improvement in skin tone, radiance, and/or clarity; (f) improvement in procollagen and/or collagen production; (g) improvement in maintenance and remodeling of elastin; (h) improvement in skin texture and/or promotion of re-texturization; (i) improvement in skin barrier repair and/or function; (j) improvement in appearance of skin contours; (k) restoration of skin luster and/or brightness; (I) replenishment of essential nutrients and/or constituents in the skin; (m) improvement of skin appearance decreased by aging and/or menopause; (n) improvement in skin moisturization and/or hydration;
  • the extract may be present in an amount from about 0.0001 wt% to about 90 wt% based on the total weight of the composition, and in a further embodiment may be present in an amount of from about 0.01 wt% to about 10 wt% of the total weight of the composition.
  • the Hoya carnosa plant extract may be derived from the whole of the Hoya carnosa plant.
  • Another embodiment of the current invention is directed to a method of improving the barrier function and viability of the skin by topically applying to the skin the above-noted composition in an amount effective to increase collagen synthesis, increase epidermis thickness, or any combination thereof.
  • the extract is derived from whole of the Hoya carnosa plant.
  • the plant extract is present in an amount of about 0.0001 wt% to about 90 wt% based on the total weight of the composition, and in still further embodiments, the plant extract is present in an amount of about 0.01 wt% to about 10 wt% based on the total weight of the composition.
  • a further embodiment of the current method is directed to treating wrinkles, fine lines, or a sagging skin, by topically applying to the skin the above- noted composition in an amount effective to treat the skin in need thereof.
  • a further embodiment of the current invention is directed to a method of treating skin comprising topically applying to an area of the skin in need thereof an effective amount of a Hoya carnosa extract that modulates a skin biomarker, wherein the ability of the Hoya carnosa extract to modulate a skin biomarker has been determined by an assay which measures the amount of change in a skin biomarker selected from the group comprising epidermal thickening; total collagen; and procollagen in skin cells and/or skin cell pre-differentiation precursors that have been contacted with the Hoya carnosa extract.
  • a method for treating a skin condition characterized by insufficient subcutaneous lipids comprising topically applying to skin in need thereof an effective amount of at least one Hoya carnosa extract.in a cosmetically acceptable vehicle for a time sufficient to improve the aesthetic appearance of said skin.
  • FIG. 1 is a HPLC profile of an extract of Hoya carnosa.
  • the successful restoration of youthful skin must address a variety of key issues including: vitality of fibroblasts and keratinocytes, cell-cell adhesion in the epidermis and dermis, cell nourishment to the epidermis, cell-cell anchoring and adhesion between keratinocytes, communication between the dermis and epidermis, collagenase overproduction, collagen replacement, and mechanical properties of the skin.
  • the present invention addresses these key issues through the use of cosmetic compositions incorporating extracts of Hoya carnosa.
  • the compositions of the current invention are used to reduce fine lines, wrinkles, and sagging, and improve skin tone and to improve the overall appearance of skin.
  • the extracts of Hoya carnosa stimulate the production of collagen and/or increase epidermis thickness.
  • compositions for topical application which comprise an effective amount of an extract of Hoya carnosa to treat, reverse, ameliorate and/or prevent signs of skin damage or skin aging.
  • Such benefits include without limitation, the following:
  • compositions of the invention are applied to skin in need of treatment. That is, skin which suffers from a deficiency or loss in any of the foregoing attributes or which would otherwise benefit from improvement in any of the foregoing skin attributes.
  • the composition is intended for use as a non- therapeutic treatment.
  • the composition is an article intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human bodyfor cleansing, beautifying, promoting attractiveness, or altering the appearance, in accordance with the US FD&C Act, sec. 201 (i).
  • active amount refers to the amount of Hoya carnosa extract absent diluent, solvent, carrier, filler or any other ingredient.
  • An “amount effective” or an “effective amount” to provide a particular anti-aging benefit to the skin refers to the "active amount" of extract required to provide a clinically measurable improvement in the particular manifestation of aging, i.e., an unwanted feature associated with aging, when applied or administered for a time sufficient to provide a clinically measurable improvement in the particular manifestation of aging.
  • a person in need thereof refers to an individual with a normal but noticeable and undesired skin condition, unwanted feature, due to aging, e.g. lines and wrinkles, sagging, dullness, discoloration, uneven tone, rough texture, etc., or an individual that elects to decrease the effects of aging in the absence of a noticeable and undesired skin condition, i.e. as a preventative or prophylactic.
  • cosmetically acceptable it is meant that a particular component is generally regarded as safe and nontoxic at the levels employed.
  • the term "discoloration” includes discrete pigmentation and mottled pigmentation.
  • Discrete pigmentation are distinct uniform areas of darker pigment and may appear as brown spots or freckles on the skin and may include solar lentigo, darkened spots on the skin caused by aging and the sun also known as “liver spots,” “senile freckles,” or “age spots,” or ephelis, freckles.
  • Mottled pigmentation are dark blotches that are larger and more irregular in size and shape than discrete pigmentation and may include conditions such as chloasma, melasma, skin discolorations caused by hormones, i.e. as the result of pregnancy, birth control pills, or estrogen replacement therapy.
  • the discoloration may be the result of external factors including, but not limited to, UV-R, tanning and photoaging, drugs, and/or chemicals, or internal factors including, but not limited to, genetics, hormonal influences, and/or inflammation.
  • Elasticity of the skin refers to the springiness and resilience of skin's ability to regain its original shape and size after deformation. Elasticity of the skin may be evaluated by a pinch test that can either cause deformation by stretching or squeezing the skin.
  • essential oil refers to the volatile ethereal fraction obtained from a plant or plant part by a physical separation process such as distillation or chromatographic separation.
  • the essential oils are typically terpenoids often comprising monoterpenes and have the odor and flavor of the plant from which they were extracted.
  • prevention refers to affording skin not yet affected by the condition a benefit that serves to avoid, delay, forestall, minimize, or reduce the recurrence/ onset of one or more unwanted features associated with the skin condition to be prevented.
  • Such preventative benefits include, for example, delaying development and/or recurrence of the condition, or reducing the duration, severity, or intensity of one or more unwanted features associated with the condition if it eventually develops.
  • prevention is not meant to imply that all subjects in a subject population administered the cosmetic composition will never be affected by or develop the cosmetic or dermatologic conditions, damage, effect, or symptom, but rather that the subject population will exhibit a reduction in the cosmetic or dermatologic damages, effects, or symptoms.
  • many flu vaccines are not 100% effective at preventing flu in those administered the vaccine.
  • Preventing aging refers to affording not yet affected skin a benefit that serves to avoid, delay, forestall, or minimize one or more unwanted features associated with aging, such as reducing the extent of lines and wrinkles, sagging, dullness, discoloration, uneven tone, rough texture, and/or fragileness that eventually develops at the treated area.
  • skin as used herein includes the skin on or in the face, mouth, neck, chest, back, arms, hands, legs, and scalp.
  • Thin skin is intended to include skin that is thinned due to chronological aging, menopause, or photo- damage.
  • Treating skin aging or damage refers to eradicating, reducing, ameliorating, or reversing one or more of the unwanted features associated with aging.
  • Unwanted features associated with aging skin e.g., lines and wrinkles, sagging, dullness, uneven tone, discoloration, and/or rough texture.
  • Treatment benefits include, e.g., reducing the appearance of lines, wrinkles, and/or sagging, restoring luster to the skin, evening the tone of skin, softening the skin texture, and/or reducing pigmentation.
  • the present compositions and methods are suitable for use in treating dermatological conditions of the skin in numerous areas of the body, including, without limitation the face, forehead, lips neck, arms hands, legs, knees, feet chest, back, groin, buttocks, and the like. In one embodiment, the compositions are applied to the face.
  • wrinkle refers to both fine wrinkling and coarse wrinkling.
  • Fine wrinkling or fine lines refers to superficial lines and wrinkles on the skin surface.
  • Coarse wrinkling refers to deep furrows, particularly deep lines/wrinkles on the face and around the eyes, including expression lines such as frown lines and wrinkles, forehead lines and wrinkles, crow's feet lines and wrinkles, nasolabial fold and marionette lines and wrinkles.
  • Forehead lines and wrinkles refer to superficial lines and/or deep furrows on skin of the forehead.
  • Crow's feet lines and wrinkles refer to superficial lines and/or deep furrows on skin around the eye area.
  • Marionette lines and wrinkles refer to superficial lines and/or deep furrows on skin around the mouth. Wrinkles can be assessed for number, length, and depth of the lines.
  • the cosmetic compositions used in the method of the current invention comprise a botanical component derived from the Hoya carnosa plant.
  • Hoya carnosa plant may be in any form including, but not limited to, the whole plant, a dried plant, a ground plant or parts thereof, including but not limited to, seeds, needles, leaves, roots, bark, cones, stems, rhizomes, callus cells, protoplasts, organs and organ systems, and meristems, an extract, a dried extract, a synthetic extract, or components and/or constituents found in, or isolated from, the plant, and/or portions of the plant, or extracts derived either directly or synthetically from the plant, or any combinations thereof.
  • the botanical component is in one embodiment derived directly from the Hoya carnosa plants.
  • the botanical component may be in a pure form, a semi-pure form, or unpurified form.
  • the Hoya carnosa botanical component may be in the form of a liquid, a semi-solid, or a solid consistency.
  • the botanical component may be an essential oil.
  • the raw materials may be collected from the whole of the Hoya carnosa plants (i.e. stems, leaves, roots, flowers, etc.), and in certain embodiments the raw materials are primarily or solely obtained from the leaves and stems of Hoya carnosa..
  • the raw materials collected from the Hoya carnosa plants are ground to small particle sizes.
  • the raw materials may be dried to reduce water content.
  • the raw materials may be air-dried, oven-dried, rotary evaporated under vacuum, lyophilized, or dried by any other suitable method known in the art.
  • the extract of Hoya carnosa may be obtained by distilling the raw materials with a stripping agent.
  • the stripping agent may be a liquid that is miscible, immiscible, or partially miscible with the desired extract from Hoya carnosa.
  • Suitable stripping agents include, but are not limited to the following: water; alcohols (such as methanol, ethanol, propanol, butanol and the like); glycols; ethers (such as diethyl ether, dipropyl ether, and the like); esters (such as butyl acetate, ethyl acetate, and the like); ketones (such as acetone, ethyl methyl ketone, and the like); dimethyl sulfoxide; acetonitrile; other organic solvents; and combinations thereof.
  • the stripping agent is immiscible with the desired extract from Hoya carnosa.
  • the Hoya carnosa extract may be collected by phase separation from the stripping agent. It is believed that the stripping agent increases the overall vapor pressure of a distillation system for obtaining an extract of Hoya carnosa and thereby reduces the boiling point of the desired product, the Hoya carnosa extract.
  • Hoya carnosa botanical component may be in the form of an extract obtained by solvent extraction, in one embodiment obtained by an organic solvent extraction.
  • the organic solvent extraction method involves washing and extracting the raw materials, which may be whole or ground into small particle sizes, using an organic solvent.
  • organic solvents include methanol, ethanol, isopropanol, dichloromethane, chloroform, hexane, xylene, and petroleum ether.
  • An extracting machine may be used for organic solvent extraction as is well known in the field. The raw materials are pushed slowly into the extracting machine by a thruster.
  • Organic solvent e.g., ethanol
  • the solvent flows toward the raw material inlet, soaks the materials and flows out from the opposite side of the solvent inlet. Since the plant materials and the solvent move in opposite directions against each other, the plant materials are constantly immersed in a solution that contains a low- concentration of extract. As a result of equilibrium, high yield of plant constituent(s) may be achieved by continuously extracting the plant material against the low- concentration solution.
  • An extraction time suitable to extract the Hoya carnosa plant constituents is used, typically between about 1 -10 hours, in one embodiment between about 2-8 hours, and in one embodiment between about 3-6 hours.
  • the temperature of extraction is between about 30°C-100°C, in one embodiment between about 40°C-70°C, and in one embodiment between about 50°C-60°C.
  • the collected extract is then fine-filtered to remove debris, and may be used directly, or is concentrated, for example by distilling the solvent or by other conventional processing.
  • the solution of extract actives may be rotary evaporated under vacuum or lyophilized.
  • a typical extract's actives content is above about 25%, in one embodiment above 50%, and the extract may also be provided as an essential oil or a concentrate having a semi-solid or solid consistency.
  • aqueous-organic solvent extraction involves initially collecting raw materials from the Hoya carnosa plants, which may be whole or ground into small particle sizes.
  • the ground plant material is soaked in aqueous solution that is acidic or alkaline, depending on the solubility and stability of the desired extract under acidic or alkaline (basic) conditions.
  • an acid such as hydrochloric acid or sulfuric acid is added to water, e.g., at a concentration of about 3% (w/v).
  • an alkali such as sodium hydroxide or sodium carbonate is added to water.
  • the extraction time and temperature of extraction are typically similar to that used in the organic solvent extraction method described above.
  • the extract is then collected and fine-filtered to remove debris.
  • Alkaline agents e.g., ammonia
  • acidifying agents e.g., sulfuric acid
  • the aqueous extract may be used directly, in concentrated or dried form.
  • organic solvent may then be added to the neutralized solution to transfer the extract from an aqueous phase to an organic phase. Examples of such organic solvents include, but are not limited to, ethanol, isopropanol, butanol, pentanol, hexanol, and xylene.
  • the extract comprising the transferred extract actives dissolved in organic solvent may be used directly as an essential oil or a concentrate, or dried by a number of different means, such as, for example, air-drying, oven-drying, rotary evaporating under vacuum or lyophilizing to a semi-solid or solid consistency.
  • the Hoya carnosa extract as used herein also includes "synthetic" extracts, i.e., various combinations of known Hoya carnosa plant components and/or constituents that are combined to substantially mimic the composition and/or activity of a Hoya carnosa plant extract of natural origin.
  • the synthetic extracts have substantially the same number of active components as a natural Hoya carnosa plant material. The correspondence of the numerical incidence of actives between the synthetic extracts and the natural Hoya carnosa plant material may also be described in terms of "percent commonality.”
  • the synthetic extract has about 50 percent or more commonality to the chemical composition of a plant or natural extract.
  • the synthetic extract has about 50 percent or more of the active ingredients found in the plant or a natural extract.
  • the chemical composition of the synthetic extract has about 70 percent or more commonality to the chemical composition of a plant or a natural extract.
  • a synthetic extract has about 90 percent or more commonality to the chemical composition of a plant or a natural extract.
  • compositions according to the invention can be formulated in a variety of forms for topical application and will comprise from about 0.0001 % to about 90% by weight of an extract of Hoya carnosa, and in one embodiment will comprise from about 0.0005% to about 25% by weight, and in one embodiment from about 0.001 % to about 10% by weight.
  • the composition may comprise a Hoya carnosa extract within a range from about 0.005%, 0.01 %, 0.05%, 0.1 %, 0.25%, 0.5%, 0.75% or 1 % up to 5%, 7.5% or 10% by weight of the total composition.
  • compositions will comprise an effective amount of an extract of Hoya carnosa, by which is meant an amount sufficient to reduce and/or inhibit the appearance of signs of aging or damage in a given area of skin when topically applied thereto.
  • the above amounts refer to an "active amount" of a Hoya carnosa extract.
  • compositions comprising components from the Hoya carnosa plant include, but are not limited to, topically applied formulations, anti-oxidants, anti-inflammatories, sunscreens, cosmetics (including makeup), personal care products (e.g., antiperspirants or deodorants for controlling body odor), topicals, skin penetration enhancers, and the like.
  • the Hoya carnosa plant components and additional ingredients comprising such compositions may be formulated in a variety of product forms.
  • the compositions may be prepared in targeted delivery systems, e.g. creams, lotions, gels, toners, serums, transdermal patches, and the like, particularly for topical administration. Targeted delivery and/or penetration enhancement may also be achieved by iontophoresis.
  • the present invention further provides the compositions comprising the Hoya carnosa plant components for the current method be in one embodiment topically administered for targeted delivery.
  • the method of the current invention is suitable for all skin types, such as sensitive, normal, oily, or combination.
  • the compositions may be in one embodiment applied to sensitive skin or hair types.
  • the compositions are applied to the skin or hair for a period of time sufficient to improve the aesthetic appearance of conditions related to skin, including unwanted features associated aging, e.g. lines and wrinkles, sagging, dullness, uneven tone, discoloration, and/or rough texture.
  • the compositions may be applied topically once, twice, or more daily, in one embodiment once a day.
  • the daily application may be applied for a period of one week, two weeks, four weeks, or more.
  • compositions may be formulated into liposomes which can comprise other additives or substances, and/or which can be modified to more specifically reach or remain at a site following administration.
  • the compositions of the present invention yield improvements to the aesthetic appearance by treating at least one of the unwanted features related to skin aging or damage.
  • compositions comprising a cosmetically or dermatologically acceptable formulation which is suitable for contact with living animal tissue, including human tissue, with virtually no adverse physiological effect to the user.
  • compositions embraced by this invention can be provided in any cosmetically and/or dermatologically suitable form, in one embodiment as a lotion or cream, but also in an anhydrous or aqueous base, as well as in a sprayable liquid form.
  • compositions used in this invention include, for example, an emulsion, a cream, a balm, a gloss, a lotion, a mask, a serum, a toner, an ointment, a mousse, a patch, a pomade, a solution, a spray, a wax-based stick, or a towelette.
  • compositions can include one or more compatible cosmetically acceptable adjuvants commonly used and known by the skilled practitioner, such as colorants, fragrances, emollients, humectants, preservatives, vitamins, chelators, thickeners, perilla oil or perilla seed oil (WO 01/66067 to a "Method of Treating a Skin Condition," incorporated herewith in its entirety for all purposes) and the like, as well as other botanicals such as aloe, chamomile, and the like, and as further described below.
  • compatible cosmetically acceptable adjuvants commonly used and known by the skilled practitioner, such as colorants, fragrances, emollients, humectants, preservatives, vitamins, chelators, thickeners, perilla oil or perilla seed oil (WO 01/66067 to a "Method of Treating a Skin Condition," incorporated herewith in its entirety for all purposes) and the like, as well as other botanicals such as aloe, chamomile, and the like
  • transdermal modes of delivery such as patches and the like, with or without a suitable penetration enhancer.
  • the methods and compositions embodied by the invention provide a means by which the Hoya carnosa components can be effectively administered in a transdermal system.
  • a transdermal means of delivering a composition or formulation (often with a penetration enhancing composition) to the skin is that of the transdermal patch or a similar device as known and described in the art.
  • Transdermal patches are designed to deliver an effective amount of compound across a user's skin.
  • Transdermal patches typically involve a liquid, gel, solid matrix, or pressure-sensitive adhesive carrier into which the Hoya carnosa extract may be incorporated.
  • Patch formulations and preparations are well known in the art. See for example “Dermatological and Transdermal Formulations” (Drugs and the Pharmaceutical Sciences, Vol 1 19) by Kenneth A Walters (Editor), Marcel Dekker and “Transdermal Drug Delivery” (Drugs & the Pharmaceutical Sciences) by Richard H. Guy (Editor), Jonathan Hadgraft (Editor) 2nd Rev & ex edition Marcel Dekker and "Mechanisms of Transdermal Drug Delivery” (Drugs & the Pharmaceutical Sciences, Vol 83) edited by Russell O. Potts and Richard H. Guy (1997). Examples of such devices are disclosed in U.S. Pat. Nos.
  • the transdermal mode of storing and delivering the compositions onto the skin, including hair, and forming the active composition is convenient and well-suited for the purposes of an embodiment of the present invention.
  • the application occurs through a sustained release vehicle, carrier, or diluent, e.g., a topically applied sustained released patch.
  • a topical patch when used, the patch is applied to the desired area for extended period of time.
  • the extended period of time is greater than one hour, most in one embodiment the extended period of time is overnight, i.e., when the user is sleeping.
  • the transdermal patches may be formulated to provide extended benefits for a period of about 1 -7 days, in one embodiment, about 2 to 7 days, in one embodiment about 3-7 days.
  • the topical compositions can include one or more cosmetically acceptable vehicles.
  • vehicles may take the form of any known in the art suitable for application to skin and may include water (e.g., deionized water); vegetable oils; mineral oils; esters such as octal palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dicapryl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, cetearyl alcohol, stearyl alcohol and biphenyl alcohol; isoparaffins such as isooctane, isododecane and is hexadecane; silicone oils such as cyclomethicone, dimethicone, dimethicone cross-polymer, polysiloxanes and their derivatives, in one embodiment organomodified derivatives; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyisobutene
  • the vehicle may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase or mixtures thereof.
  • the cosmetically acceptable vehicle may also comprise an emulsion.
  • suitable emulsions include water-in- oil emulsions, oil-in-water emulsions, silicone-in-water emulsions, water-in-silicone emulsions, wax-in-water emulsions, water-oil -water triple emulsions or the like having the appearance of a cream, gel or microemulsions.
  • the emulsion may include an emulsifier, such as a nonionic, anionic or amphoteric surfactant.
  • the oil phase of the emulsion in one embodiment has one or more organic compounds, including emollients; humectants (such as butylene glycol, propylene glycol, Methyl gluceth-20, and glycerin); other water-dispersible or water- soluble components including thickeners such as veegum or hydroxyalkyl cellulose; gelling agents, such as high MW polyacrylic acid, i.e. CARBOPOL 934; and mixtures thereof.
  • the emulsion may have one or more emulsifiers capable of emulsifying the various components present in the composition.
  • the compounds suitable for use in the oil phase include without limitation, vegetable oils; esters such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dicapryl ether; fatty alcohols such as cetyl alcohol, stearyl alcohol and behenyl alcohol; isoparaffins such as isooctane, isododecane and isohexadecane; silicone oils such as dimethicones, cyclic silicones, and polysiloxanes; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyisobutene; natural or synthetic waxes; and the like.
  • Suitable hydrophobic hydrocarbon oils may be saturated or unsaturated, have an aliphatic character and be straight or branched chained or contain alicyclic or aromatic rings.
  • the oil- containing phase may be composed of a singular oil or mixtures of different oils.
  • Hydrocarbon oils include those having 6-20 carbon atoms, in one embodiment 10-16 carbon atoms.
  • Representative hydrocarbons include decane, dodecane, tetradecane, tridecane, and C 8 -2o isoparaffins.
  • Paraffinic hydrocarbons are available from Exxon under the ISOPARS trademark, and from the Permethyl Corporation.
  • C 8 -2o paraffinic hydrocarbons such as d 2 isoparaffin (isododecane) manufactured by the Permethyl Corporation having the tradename Permethyl 99ATM are also contemplated to be suitable.
  • Various commercially available Ci6 isoparaffins, such as isohexadecane (having the tradename Permethyl®) are also suitable.
  • volatile hydrocarbons examples include polydecanes such as isododecane and isodecane, including for example, Permethyl-99A (Presperse Inc.) and the C 7 -Cs through C12-C15 isoparaffins such as the Isopar Series available from Exxon Chemicals.
  • a representative hydrocarbon solvent is isododecane.
  • the oil phase may comprise one or more waxes, including for example, rice bran wax, carnauba wax, ouricurry wax, candelilla wax, montan waxes, sugar cane waxes, ozokerite, polyethylene waxes, Fischer-Tropsch waxes, beeswax, microcrystalline wax, silicone waxes, fluorinated waxes, and any combination thereof.
  • waxes including for example, rice bran wax, carnauba wax, ouricurry wax, candelilla wax, montan waxes, sugar cane waxes, ozokerite, polyethylene waxes, Fischer-Tropsch waxes, beeswax, microcrystalline wax, silicone waxes, fluorinated waxes, and any combination thereof.
  • Non-limiting emulsifiers include emulsifying waxes, emulsifying polyhydric alcohols, polyether polyols, polyethers, mono- or di-ester of polyols, ethylene glycol mono-stearates, glycerin mono-stearates, glycerin di-stearates, silicone-containing emulsifiers, soya sterols, fatty alcohols such as cetyl alcohol, acrylates, fatty acids such as stearic acid, fatty acid salts, and mixtures thereof.
  • the emulsifiers may include soya sterol, cetyl alcohol, stearic acid, emulsifying wax, acrylates, silicone containing emulsifiers and mixtures thereof.
  • Other specific emulsifiers that can be used in the composition of the present invention include, but are not limited to, one or more of the following: C-io-30 alkyl acrylate crosspolymer; Dimethicone PEG-7 isostearate, acrylamide copolymer; mineral oil; sorbitan esters; polyglyceryl-3-diisostearate; sorbitan monostearate, sorbitan tristearate, sorbitan sesquioleate, sorbitan monooleate; glycerol esters such as glycerol monostearate and glycerol monooleate; polyoxyethylene phenols such as polyoxyethylene octyl phenol and polyoxyethylene nonyl phenol; polyoxyethylene ethers such as polyoxyethylene
  • emulsifiers typically will be present in the composition in an amount from about 0.001 % to about 10% by weight, in particular in an amount from about 0.01 % to about 5% by weight, and more in one embodiment, from about 0.1 % to about 3% by weight.
  • the oil phase may comprise one or more volatile and/or non-volatile silicone oils.
  • Volatile silicones include cyclic and linear volatile dimethylsiloxane silicones.
  • the volatile silicones may include cyclodimethicones, including tetramer (D 4 ), pentamer (D5), and hexamer (De) cyclomethicones, or mixtures thereof. Particular mention may be made of the volatile cyclomethicone- hexamethyl cyclotrisiloxane, octamethyl-cyclotetrasiloxane, and decamethyl- cyclopentasiloxane.
  • Suitable dimethicones are available from Dow Corning under the name Dow Corning 200® Fluid and have viscosities ranging from 0.65 to 600,000 centistokes or higher.
  • Suitable non-polar, volatile liquid silicone oils are disclosed in U.S. Pat. No. 4,781 ,917, herein incorporated by reference in its entirety. Additional volatile silicones materials are described in Todd et al., "Volatile Silicone Fluids for Cosmetics", Cosmetics and Toiletries, 91 :27-32 (1976), herein incorporated by reference in its entirety.
  • Linear volatile silicones generally have a viscosity of less than about 5 centistokes at 25° C, whereas the cyclic silicones have viscosities of less than about 10 centistokes at 25° C.
  • volatile silicones of varying viscosities include Dow Corning 200, Dow Corning 244, Dow Corning 245, Dow Corning 344, and Dow Corning 345, (Dow Corning Corp.); SF-1204 and SF-1202 Silicone Fluids (G.E. Silicones), GE 7207 and 7158 (General Electric Co.); and SWS-03314 (SWS Silicones Corp.).
  • Linear, volatile silicones include low molecular weight polydimethylsiloxane compounds such as hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane, and dodecamethylpentasiloxane, to name a few.
  • Non-volatile silicone oils will typically comprise polyalkylsiloxanes, polyarylsiloxanes, polyalkylarylsiloxanes, or mixtures thereof. Polydimethylsiloxanes are in one embodiment non-volatile silicone oils. The non-volatile silicone oils will typically have a viscosity from about 10 to about 60,000 centistokes at 25° C, in one embodiment between about 10 and about 10,000 centistokes, in one embodiment between about 10 and about 500 centistokes; and a boiling point greater than 250° C. at atmospheric pressure.
  • Non limiting examples include dimethyl polysiloxane (dimethicone), phenyl trimethicone, and diphenyldimethicone.
  • volatile and nonvolatile silicone oils may optionally be substituted with various functional groups such as alkyl, aryl, amine groups, vinyl, hydroxyl, haloalkyl groups, alkylaryl groups, and acrylate groups, to name a few.
  • the water-in-silicone emulsion may be emulsified with a nonionic surfactant (emulsifier) such as, for example, polydiorganosiloxane-polyoxyalkylene block copolymers, including those described in U.S. Pat. No. 4,122,029, the disclosure of which is hereby incorporated by reference.
  • a nonionic surfactant emulsifier
  • polydiorganosiloxane-polyoxyalkylene block copolymers including those described in U.S. Pat. No. 4,122,029, the disclosure of which is hereby incorporated by reference.
  • emulsifiers generally comprise a polydiorganosiloxane backbone, typically polydimethylsiloxane, having side chains comprising — (EO)m— and/or — (PO)n— groups, where EO is ethyleneoxy and PO is 1 ,2-propyleneoxy, the side chains being typically capped or terminated with hydrogen or lower alkyl groups (e.g., C1 -6, typically C1 -3).
  • EO ethyleneoxy
  • PO 1 ,2-propyleneoxy
  • suitable water-in-silicone emulsifiers are disclosed in U.S. Pat. No. 6,685,952, the disclosure of which is hereby incorporated by reference herein.
  • water-in-silicone emulsifiers include those available from Dow Corning under the trade designations 3225C and 5225C FORMULATION AID; SILICONE SF-1528 available from General Electric; ABIL EM 90 and EM 97, available from Goldschmidt Chemical Corporation (Hopewell, Va.); and the SILWET series of emulsifiers sold by OSI Specialties (Danbury, Conn.).
  • water-in-silicone emulsifiers include, but are not limited to, dimethicone PEG 10/15 crosspolymer, dimethicone copolyol, cetyl dimethicone copolyol, PEG-15 lauryl dimethicone crosspolymer, laurylmethicone crosspolymer, cyclomethicone and dimethicone copolyol, dimethicone copolyol (and) caprylic/capric triglycerides, polyglyceryl-4 isostearate (and) cetyl dimethicone copolyol (and) hexyl laurate, and dimethicone copolyol (and) cyclopentasiloxane.
  • water-in-silicone emulsifiers include, without limitation, PEG/PPG-18/18 dimethicone (trade name 5225C, Dow Corning), PEG/PPG-19/19 dimethicone (trade name BY25-337, Dow Corning), Cetyl PEG/PPG-10/1 dimethicone (trade name Abil EM-90, Goldschmidt Chemical Corporation), PEG-12 dimethicone (trade name SF 1288, General Electric), lauryl PEG/PPG-18/18 methicone (trade name 5200 FORMULATION AID, Dow Corning), PEG-12 dimethicone crosspolymer (trade name 9010 and 901 1 silicone elastomer blend, Dow Corning), PEG-10 dimethicone crosspolymer (trade name KSG-20, Shin-Etsu), dimethicone PEG-10/15 crosspolymer (trade name KSG-210, Shin-Etsu), and dimethicone PEG-7 isostearate.
  • the water-in-silicone emulsifiers typically will be present in the composition in an amount from about 0.001 % to about 10% by weight, in particular in an amount from about 0.01 % to about 5% by weight, and more in one embodiment, below 1 % by weight.
  • the aqueous phase of the emulsion may include one or more additional solvents, including lower alcohols, such as ethanol, isopropanol, and the like.
  • the volatile solvent may also be a cosmetically acceptable ester such as butyl acetate or ethyl acetate; ketones such as acetone or ethyl methyl ketone; or the like.
  • the oil-containing phase will typically comprise from about 10% to about 99%, in one embodiment from about 20% to about 85%, and more in one embodiment from about 30% to about 70% by weight, based on the total weight of the emulsion, and the aqueous phase will typically comprise from about 1 % to about 90%, in one embodiment from about 5% to about 70%, and more in one embodiment from about 20% to about 60% by weight of the total emulsion.
  • the aqueous phase will typically comprise from about 25% to about 100%, more typically from about 50% to about 95% by weight water.
  • compositions may include liposomes.
  • the liposomes may comprise other additives or substances and/or may be modified to more specifically reach or remain at a site following administration.
  • the daily doses recommended in conformity with the invention range from 0.5 to 2600 mg/day, and in one embodiment from 5 to 1200 mg/day of Hoya carnosa extract.
  • the compositions of the invention can be taken for several days, weeks or months.
  • the regimen of treatment can be repeated many times in a year and can even be continuous.
  • composition may optionally comprise other cosmetic actives and excipients, obvious to those skilled in the art including, but not limited to, fillers, emulsifying agents, antioxidants, surfactants, film formers, chelating agents, gelling agents, thickeners, emollients, humectants, moisturizers, vitamins, minerals, viscosity and/or rheology modifiers, sunscreens, keratolytics, depigmenting agents, retinoids, hormonal compounds, alpha-hydroxy acids, alpha-keto acids, anti- mycobacterial agents, antifungal agents, antimicrobials, antivirals, analgesics, lipidic compounds, anti-allergenic agents, H1 or H2 antihistamines, anti-inflammatory agents, anti-irritants, antineoplastics, immune system boosting agents, immune system suppressing agents, anti-acne agents, anesthetics, antiseptics, insect repellents, skin cooling compounds, skin protectants, skin penetration enhancer
  • composition may comprise additional active ingredients having anti-aging benefits, as it is contemplated that synergistic improvements may be obtained with such combinations.
  • anti-aging components include, without limitation, botanicals (e.g., Butea Frondosa extract); thiodipropionic acid (TDPA) and esters thereof; retinoids (e.g., all-trans retinoic acid, 9-cis retinoic acid, phytanic acid and others); hydroxy acids (including alpha-hydroxyacids and beta-hydroxyacids), salicylic acid and salicylates; exfoliating agents (e.g., glycolic acid, 3,6,9- trioxaundecanedioic acid, etc.); estrogen synthetase stimulating compounds (e.g., caffeine and derivatives); compounds capable of inhibiting 5 alpha-reductase activity (e.g., linolenic acid, linoleic acid, finasteride, and mixtures thereof); barrier function enhancing
  • the present compositions may also include skin whiteners.
  • suitable skin whiteners include, but are not limited to, one or more of the following: ascorbyl glucoside, vitamin C, retinol and/or its derivatives, arbutin, bearberry extract, rumex crispus extract, milk proteins including hydrolyzed milk proteins, N,N,S-tris(carboxym- ethyl)cysteamine, oleanolic acids, perilla oil, placenta extract, Saxifragia sarmentosa, perilla extract, juniperic acid, TDPA, Ligusticum chiangxiong heart., Asmunda japonica thunb., Stellaria medica (L.) cyr., Sedum sarmentosum bunge, Ligusticum lucidum Ait., ilex purpurea hassk, emblica, apigenin, ascorbyl palmitol, car
  • Suitable hydroxyl acids include, for example, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, 2-hydroxyalkanoic acid, mandelic acid, salicylic acid, and alkyl derivatives thereof, including 5-n-octanoylsalicylic acid, 5-n- dodecanoylsalicylic acid, 5-n-decanoylsalicylic acid, 5-n-octylsalicylic acid, 5-n- heptyloxysalicylic acid, 4-n-heptyloxysalicylic acid, and 2-hydroxy-3-methylbenzoic acid or alkoxy derivatives thereof, such as 2-hydroxy-3-methyoxybenzoic acid.
  • retinoids include, without limitation, retinoic acid (e.g., all- trans or 13-cis) and derivatives thereof, retinol (Vitamin A) and esters thereof, such as retinol palmitate, retinol acetate and retinol propionate, and salts thereof.
  • retinoic acid e.g., all- trans or 13-cis
  • retinol Vitamin A
  • esters thereof such as retinol palmitate, retinol acetate and retinol propionate, and salts thereof.
  • the topical compositions of the present invention may also include one or more of the following: a skin penetration enhancer, an emollient, a skin plumper, an optical diffuser, a sunscreen, an exfoliating agent, and an antioxidant.
  • An emollient provides the functional benefits of enhancing skin texture (smoothness) and reducing the appearance of fine lines and coarse wrinkles.
  • Examples include isopropyl myristate, petrolatum, isopropyl lanolate, silicones (e.g., methicone, dimethicone), oils, mineral oils, fatty acid esters, cetyl ethylhexanoate, C-12-15 alkyl benzoate, isopropyl isostearate, diisopropyl dimer dillinoeate, or any mixtures thereof.
  • the emollient may be in one embodiment present from about 0.1 wt % to about 50 wt % of the total weight of the composition.
  • a skin plumper serves as a collagen enhancer to the skin.
  • An example of a suitable and in one embodiment skin plumper is palmitoyi oligopeptide.
  • Other skin plumpers are collagen and/or other glycosaminoglycan (GAG) enhancing agents.
  • the skin plumper may comprise from about 0.1 wt % to about 20 wt % of the total weight of the composition.
  • An optical diffuser is a particle that changes the surface optometries of skin, resulting in a visual blurring and softening of, for example, lines and wrinkles.
  • optical diffusers that can be used in the present invention include, but are not limited to, boron nitride, mica, nylon, polymethylmethacrylate (PMMA), polyurethane powder, sericite, silica, silicone powder, talc, Teflon, titanium dioxide, zinc oxide, or any mixtures thereof.
  • the optical diffuser may be present from about 0.01 wt % to about 20 wt % of the total weight of the composition.
  • sunscreens are those with a broad range of UVB and UVA protection, such as octocrylene, avobenzone (Parsol 1789), octyl methoxycinnamate, octyl salicylate, oxybenzone, homosylate, benzophenone, camphor derivatives, zinc oxide, and titanium dioxide.
  • the sunscreen may comprise from about 0.01 wt % to about 70 wt % of the composition.
  • Suitable exfoliating agents include, for example, alpha-hydroxyacids, beta-hydroxyacids, oxaacids, oxadiacids, and their derivatives such as esters, anhydrides and salts thereof.
  • Suitable hydroxy acids include, for example, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, 2-hydroxyalkanoic acid, mandelic acid, salicylic acid and derivatives thereof.
  • a in one embodiment exfoliating agent is glycolic acid.
  • the exfoliating agent may comprise from about 0.1 wt % to about 80 wt % of the composition.
  • antioxidants functions, among other things, to scavenge free radicals from skin to protect the skin from environmental aggressors.
  • antioxidants that may be used in the present compositions include compounds having phenolic hydroxy functions, such as ascorbic acid and its derivatives/esters; alpha-hydroxyacids; beta-carotene; catechins; curcumin; ferulic acid derivatives (e.g.
  • ethyl ferulate, sodium ferulate gallic acid derivatives (e.g., propyl gallate); lycopene; reductic acid; rosmarinic acid; tannic acid; tetrahydrocurcumin; tocopherol and its derivatives (e.g., tocopheryl acetate); uric acid; or any mixtures thereof.
  • suitable antioxidants are those that have one or more thiol functions (— SH), in either reduced or non-reduced form, such as glutathione, lipoic acid, thioglycolic acid, and other sulfhydryl compounds.
  • the antioxidant may be inorganic, such as bisulfites, metabisulfites, sulfites, or other inorganic salts and acids containing sulfur.
  • Compositions of the present invention may comprise an antioxidant in one embodiment from about 0.001 wt % to about 10 wt %, and more in one embodiment from about 0.01 wt % to about 5 wt %, of the total weight of the composition.
  • additional actives may include a collagen stimulator and/or an elastin stimulator, e.g., a substance that stimulates elastin production, and/or a glycosaminoglycan enhancer.
  • elastin stimulator e.g., a substance that stimulates elastin production
  • glycosaminoglycan enhancers include, e.g., fennel extract, carrot extract, and alfalfa extract.
  • the additional actives may include a collagenase inhibitor and/or elastase inhibitor.
  • the cosmetic compositions can further comprise at least one collagen and/or elastin stimulator.
  • collagen or elastin stimulators are effective in, for example, providing improvement in procollagen and/or collagen production and/or improvement in maintenance and remodeling of elastin.
  • Colorants may include, for example, organic and inorganic pigments and pearlescent agents.
  • Suitable inorganic pigments include, but are not limited to, titanium oxide, zirconium oxide, and cerium oxide, as well as zinc oxide, iron oxide, chromium oxide and ferric blue.
  • Suitable organic pigments include barium, strontium, calcium, aluminium lakes and carbon black.
  • Suitable pearlescent agents include mica coated with titanium oxide, iron oxide, or natural pigments.
  • Fillers are normally present in an amount of about 0 weight % to about 20 weight %, based on the total weight of the composition, in one embodiment about 0.1 weight % to about 10 weight %.
  • Suitable fillers include without limitation the following: silica, treated silica, talc, zinc stearate, mica, kaolin, Nylon powders such as OrgasolTM, polyethylene powder, TeflonTM, starch, boron nitride, copolymer microspheres such as ExpancelTM (Nobel Industries), PolytrapTM (Dow Corning) and silicone resin microbeads (TospearlTM from Toshiba), and the like.
  • the compositions may include additional skin actives such as, but not limited to, botanicals, keratolytic agents, desquamating agents, keratinocyte proliferation enhancers, collagenase inhibitors, elastase inhibitors, depigmenting agents, anti-inflammatory agents, steroids, antiacne agents, antioxidants, salicylic acid or salicylates, anti-lipid agents, thiodipropionic acid or esters thereof, and advanced glycation end-product (AGE) inhibitors.
  • additional skin actives such as, but not limited to, botanicals, keratolytic agents, desquamating agents, keratinocyte proliferation enhancers, collagenase inhibitors, elastase inhibitors, depigmenting agents, anti-inflammatory agents, steroids, antiacne agents, antioxidants, salicylic acid or salicylates, anti-lipid agents, thiodipropionic acid or esters thereof, and advanced glycation end-product (AGE) inhibitors.
  • the composition may comprise at least one additional botanical, such as, for example, a botanical extract, an essential oil, or the plant itself.
  • Suitable botanicals include, without limitation, extracts from Abies pindrow, Acacia catechu, Anogeissus latifolia, Asmunda japonica, Azadirachta indica, Butea frondosa, Butea monosperma, Cedrus deodara, Emblica officinalis, Ficus benghalensis, Glycyrrhiza glabra, Ilex purpurea Hassk, Inula racemosa, Ligusticum chuangxiong, Ligusticum lucidum, Mallotus philippinensis, Mimusops elengi, Morinda citrifolia, Moringa oleifera, Naringi crenulata, Nerium indicum, Psoralea corylifolia, Stenoloma chu
  • vitamins such as tocopherol and ascorbic acid
  • vitamin derivatives such as ascorbyl monopalmitate
  • thickeners such as hydroxyalkyl cellulose
  • gelling agents such as bentonite, smectite, magnesium aluminum silicate and lithium magnesium silicate
  • metal chelating agents such as EDTA
  • pigments such as zinc oxide and titanium dioxide
  • colorants such as emollients; and humectants.
  • the composition is essentially free of components having a strong oxidizing potential, including for example, organic or inorganic peroxides. "Essentially free of these components means that the amounts present are insufficient to have a measurable impact on the activity of an extract of Hoya carnosa. In some embodiments, this will be, in relation to the amount of Hoya carnosa, less than 1 % by weight.
  • the composition of the invention comprising an extract of Hoya carnosa may have a pH between about 1 and about 8.
  • the pH of the composition will be acidic, i.e., less than 7.0, and in one embodiment will be between about 2 and about 7, more in one embodiment between about 3.5 and about 5.5.
  • the invention provides a method for treating aging skin by topically applying a composition comprising an extract of Hoya carnosa, in one embodiment in a cosmetically acceptable vehicle, over the affected area for a period of time sufficient to reduce, ameliorate, reverse or prevent dermatological signs of aging.
  • This method is particularly useful for treating signs of skin photoaging and intrinsic aging.
  • the improvement in the condition and/or aesthetic appearance is selected from the group consisting of: reducing dermatological signs of chronological aging, photo-aging, hormonal aging, and/or actinic aging; preventing and/or reducing the appearance of lines and/or wrinkles; reducing the noticeability of facial lines and wrinkles, facial wrinkles on the cheeks, forehead, perpendicular wrinkles between the eyes, horizontal wrinkles above the eyes, and around the mouth, marionette lines, and particularly deep wrinkles or creases; preventing, reducing, and/or diminishing the appearance and/or depth of lines and/or wrinkles; improving lipid accumulation in adipocytes; improving the appearance of suborbital lines and/or periorbital lines; reducing the appearance of crow's feet; rejuvenating and/or revitalizing skin, particularly aging skin; reducing skin fragility; preventing and/or reversing of loss of glycosaminoglycans and/or collagen; ameliorating the effects of estrogen imbalance; preventing skin at
  • composition will typically be applied to the skin one, two, or three times daily for as long as is necessary to achieve desired anti-aging results.
  • the treatment regimen may comprise daily application for at least one week, at least two weeks, at least four weeks, at least eight weeks, or at least twelve weeks. Chronic treatment regimens are also contemplated.
  • a composition comprising an extract of Hoya carnosa is topically applied to an "individual in need thereof," by which is meant an individual that stands to benefit from reducing visible signs of skin damage or aging.
  • the Hoya carnosa extract is provided in a pharmaceutically, physiologically, cosmetically, and dermatologically-acceptable vehicle, diluent, or carrier, where the composition is topically applied to an affected area of skin and left to remain on the affected area in an amount effective for improving the condition and aesthetic appearance of skin.
  • methods for treating fine lines and wrinkles comprise topically applying the inventive compositions comprising a Hoya carnosa extract to the skin of an individual in need thereof, e.g., topically application directly to the fine line and/or wrinkle in an amount and for a time sufficient to reduce the severity of the fine lines and/or wrinkles or to prevent or inhibit the formation of new fine lines and/or wrinkles.
  • the effect of a composition on the formation or appearance of fine lines and wrinkles can be evaluated qualitatively, e.g., by visual inspection, or quantitatively, e.g., by microscopic or computer assisted measurements of wrinkle morphology (e.g., the number, depth, length, area, volume and/or width of wrinkles per unit area of skin).
  • This embodiment includes treatment of wrinkles on the skin of the hands, arms, legs, neck, chest, and face, including the forehead.
  • compositions of the invention will be useful for treating thin skin by topically applying the composition to thin skin of an individual in need thereof.
  • the treatment is for thin skin in men, whereas other embodiments treat thin skin in women, pre-menopausal or postmenopausal, as it is believed that skin thins differently with age in men and women, and in particular in women at different stages of life.
  • the method of the invention may be employed prophylactically to forestall aging including in patients that have not manifested signs of skin aging, most commonly in individuals under 25 years of age.
  • the method may also reverse or treat signs of aging once manifested as is common in patients over 25 years of age.
  • the concentrated solution was then diluted with pure water to 1500 ml of volume and sonicated for 20 minutes to generate an aqueous suspension.
  • the suspension was left to stand at 4°C for 12 h and then centrifuged.
  • the supernatant was then transferred to a separation funnel where three separate extraction were done with 500 ml of hexane each.
  • the hexane solvent was recycled, and the hexane extract was discarded.
  • H20 2 times Diaion HP-20 column volume (100 g HP-20 is equal to 210 ml of column volume);
  • An amount (g) of chopped Hoya carnosai lowers may be gathered and pulverized. Subsequently, reflux extraction, using methods known to those of ordinary skill in the art, may be conducted using 8-1 Ox the weight of the pulverized flowers of water at 100° C. This step may be repeated. The resulting extract may be filtered and condensed using methods known to those of ordinary skill in the art, after which the extract may undergo vacuum distillation at appropriate conditions known to those of ordinary skill in the art. Subsequently, the extract may be mixed with a suitable amount of dextrin and spray dried.
  • Example 2 In vivo up-regulation of key skin biomarkers.
  • Botanical extracts of Hoya carnosa were tested for the ability to upregulate skin biomarkers in vivo.
  • 20 healthy female Caucasian subjects aged 30- 65 with skin type II or III and mild to moderate photo damage were treated with ingredients on the dorsal forearm for 3 weeks (3 consecutive rounds of 5 x 24 hour patches under semi-occlusion).
  • Test articles and vehicles were applied in a randomized allocation on five sites on each forearm.
  • Each subject was treated with the extract of Hoya carnosa at a concentration of 0.2% formulated in Propylene Glycol/Ethanol/H 2 0 (65:25:10) vehicle and the vehicle control.
  • the application dose was 2 mg/cm 2 .
  • a 2 mm punch biopsy was obtained from each treatment site and fixed in 10% buffered formalin. Tissue samples were then embedded in paraffin, sectioned (5 micrometer thickness), processed and stained for the following skin markers - Total Collagen (by Masson Trichrome) and Procollagen. In addition, epidermal thickness was evaluated. For each marker, the treated site was compared to the vehicle site to determine the difference in the intensity of the marker. If the intensity of the marker in the treated site is higher relative to control, it indicates improvement of that biomarker. Table 2 shows the percent of subjects that had an improvement in the tested skin biomarkers after three weeks of treatment with an extract of Hoya carnosa.
  • the botanical extract of Hoya carnosa upregulated biomarkers such as epidermal thickening (35.3% of subjects exhibited an increase), collagen (45.7% of subjects exhibited an increase), and pro-collagen (33.3% of subjects exhibited an increase), in vivo when topically applied to skin. It is believed that the up-regulation of these biomarkers, which decline in aging skin, leads to an improvement in the appearance of aging or aged skin.
  • Cryopreserved human primary pre-adipocytes harvested from the subcutaneous adipose tissue of a healthy female were obtained from Zen-Bio (Research Triangle Park, NC). Following the manufacturer's instructions, the pre- adipocytes were cultured in Preadipocyte Medium containing DMEM/Ham's F-12 (1 :1 , v/v). After reaching 90% confluence, the pre-adipocytes were induced to differentiate into adipocytes by changing into Adipocyte Differentiation Medium in presence or absence of test actives. Treatment with test actives was repeated 3 days after initiation of differentiation.
  • triglycerides in the adipocytes was determined by using a triglyceride assay kit (Zen- Bio). Results were obtained in triplicate and statistical significance of results was determined using a t-test.
  • Cosmetic compositions comprising an extract of Hoya carnosa for topical application to skin are provided in Tables 3 - 4 below.
  • TDPA Thiodipropionic acid
  • Alcohol Mixture (3210&1901 92.52-7.48) Alcohol Mixture (3215&1901 92.52-7.48)
  • compositions of Tables 3 - 4 are applied to skin in need of treatment, by which is meant skin in need of an anti-aging benefit.
  • the cosmetic compositions may be applied directly to the skin in need of treatment.
  • These cosmetic compositions are applied to skin aged skin, folds, sunken appearance and/or hyperpigmented skin, two or three times daily for as long as is necessary to achieve desired anti-aging and/or skin lightening results, a treatment regimen which may comprise daily application for at least one week, at least two weeks, at least four weeks, at least eight weeks, or at least twelve weeks.
  • the exemplary cosmetic compositions may be used in chronic treatment of aged or discolored skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des procédés d'utilisation d'extraits de Hoya carnosa pour conférer un bienfait antivieillisseur à la peau et/ou améliorer une affectation de la peau résultant d'une peau vieillissante ou abîmée.
PCT/US2014/010056 2013-03-11 2014-01-02 Extraits de hoya carnosa et procédés d'utilisation WO2014163717A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/793,177 2013-03-11
US13/793,177 US8865231B2 (en) 2012-12-11 2013-03-11 Hoya carnosa extracts and methods of use

Publications (1)

Publication Number Publication Date
WO2014163717A1 true WO2014163717A1 (fr) 2014-10-09

Family

ID=51658779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/010056 WO2014163717A1 (fr) 2013-03-11 2014-01-02 Extraits de hoya carnosa et procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2014163717A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092585A1 (en) * 2008-10-14 2010-04-15 Nerium Biotechnology, Inc. Plant extraction method and compositions
JP2010090069A (ja) * 2008-10-09 2010-04-22 Shiseido Co Ltd 美白剤および皮膚外用剤
US7959953B2 (en) * 2003-10-10 2011-06-14 Access Business Group International Llc Cosmetic composition and methods
US20110286953A1 (en) * 2009-02-09 2011-11-24 Shiseido Company, Ltd. Whitening agent, anti-aging agent, and anti-oxidant agent
US20120282194A1 (en) * 2011-03-28 2012-11-08 Tiffany Florence Topical skin care formulations comprising plant extracts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959953B2 (en) * 2003-10-10 2011-06-14 Access Business Group International Llc Cosmetic composition and methods
JP2010090069A (ja) * 2008-10-09 2010-04-22 Shiseido Co Ltd 美白剤および皮膚外用剤
US20100092585A1 (en) * 2008-10-14 2010-04-15 Nerium Biotechnology, Inc. Plant extraction method and compositions
US20110286953A1 (en) * 2009-02-09 2011-11-24 Shiseido Company, Ltd. Whitening agent, anti-aging agent, and anti-oxidant agent
US20120282194A1 (en) * 2011-03-28 2012-11-08 Tiffany Florence Topical skin care formulations comprising plant extracts

Similar Documents

Publication Publication Date Title
US8709507B2 (en) Maesa japonica extracts and methods of use
EP2790666B1 (fr) Extraits de maesa japonica et procédés d'utilisation
US9034396B2 (en) Serissa japonica extracts and methods of use
US9186316B2 (en) Stephanotis jasminoides extracts and methods of use
US20150366789A1 (en) Glochidium wallichianum extracts and methods of use
US20160000696A1 (en) Sargassum muticum extracts and methods of use
US9757327B2 (en) Abutilon indicum extracts and methods of use
US20150164776A1 (en) Callistephus Chinensis Extracts and Methods of Use
US20150366788A1 (en) Calotropis gigantea extracts and methods of use
US9265716B2 (en) Hoya carnosa extracts and methods of use
US20150359732A1 (en) Vernonia cinerea extracts and methods of use
WO2014158685A2 (fr) Extraits de tetracera asiatica et procédés d'utilisation
WO2014158664A1 (fr) Extraits d'hedyotis hedyotidea pour la cosmétique
US8865231B2 (en) Hoya carnosa extracts and methods of use
US8999403B2 (en) Serissa japonica extracts and methods of use
US20150359730A1 (en) Basella alba extracts and methods of use
WO2014163717A1 (fr) Extraits de hoya carnosa et procédés d'utilisation
WO2014092685A1 (fr) Extraits de hoya carnosa et procédés d'utilisation
WO2014143375A1 (fr) Extraits de serrisa japonica et procédés d'utilisation
WO2014092681A2 (fr) Extraits de callistephus chinensis et leurs procédés d'utilisation
US20150366923A1 (en) Allamanda cathartica extracts and methods of use
US20160235659A1 (en) Antidesma bunius Extracts and Methods of Use
US20150366790A1 (en) Plumeria acuminata extracts and methods of use
US20150366787A1 (en) Sesbania aculeata extracts and methods of use
US20150359731A1 (en) Phyllanthus acidus extracts and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14779594

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14779594

Country of ref document: EP

Kind code of ref document: A1